• The National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending AQUIPTA® (atogepant), an oral tablet, as an option for the acute treatment of migraine with or without aura in adults, only if, for previous migraines: at least two triptans were tried and they did not work well enough,…
Category: Headache
European survey highlights gaps in care for women with hormonal migraine
A large European survey conducted by the European Migraine and Headache Alliance has highlighted significant gaps in diagnosis, treatment and clinical discussion of hormonally related migraine among women. The Migraine in Women Survey, launched in 2025, is the largest European study to examine the impact of hormonal life stages on migraine. The survey targeted the…
Real-world study supports fremanezumab effectiveness in migraine care in Germany and the UK
A large real-world study has found that fremanezumab is associated with substantial improvements in migraine frequency, disability and healthcare resource use among patients treated in routine clinical practice in Germany and the United Kingdom. The findings provide important evidence on the effectiveness of calcitonin gene-related peptide targeted therapies beyond clinical trials. The retrospective, non-interventional study…
First anti-CGRP preventive treatment for paediatric episodic migraine
FDA approves expanded indication for AJOVY® (fremanezumab-vfrm) 6 August 2025: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. has announced that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or…
Real-world effectiveness in migraine
Final data from Teva’s PEARL real-world study reinforce the long-term effectiveness of AJOVY® (fremanezumab) for the prevention of chronic and episodic migraine Teva Pharmaceutical Industries Ltd announced on 23rd June that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered…
Difficult-to-treat migraine: EAN presentation
New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine 21 June 2025: H. Lundbeck A/S (Lundbeck) announced the full results from the phase IV RESOLUTION trial. The trial was a randomised, placebo-controlled trial designed to evaluate the efficacy of eptinezumab versus placebo in patients with chronic migraine and associated medication-overuse…
Causal links between lifestyle factors and migraine risk
Recent research using Mendelian randomisation has shed light on causal relationships between socioeconomic, behavioural, dietary, and physical factors and the risk of developing migraines. The study provides robust evidence for targeted preventive strategies in patients prone to migraines. Methodology Researchers applied a two-sample Mendelian randomisation framework to assess 28 traits across socioeconomic, behavioural, dietary, and…
Episodic migraine in children and adolescents
Teva presents positive efficacy and safety data of AJOVY® (fremanezumab) for the prevention of episodic migraine in children and adolescents from Phase 3 SPACE trial 4 December 2024: Teva Pharmaceutical Industries Ltd presented positive data from its Phase 3 SPACE study evaluating the efficacy and safety of AJOVY® (fremanezumab) for the prevention of episodic migraine…
Triptans effective for acute migraine sufferers
Study suggests Triptans are the most effective medicine for adults who experience acute migraines Findings of a study, in which researchers looked at 137 controlled trials that tested oral drugs commonly used to treat migraines, have been published in The British Medical Journal. The trials involved a total of 89,445 patients who were given one of 17…
Ubrelvy can prevent migraines when used early
AbbVie’s Ubrelvy (ubrogepant) — which is approved to treat migraines – can also help to prevent them when used before the onset of headache pain, according to a recent study from Neurology journal. The phase 3 PRODROME Trial suggests that Ubrelvy was 73% more effective in preventing a migraine attack than a placebo. In the…
